{
  "first_published_at": "2013-12-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON350695", 
  "title": "Ponatinib (Iclusig▼): risk of vascular occlusive eventsQ", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 44, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Ponatinib (Iclusig&#9660;): risk of vascular occlusive events</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--A review of the latest data has been conducted after new information suggested that vascular occlusive events occur at a higher cumulative incidence than initially observed at the time of licensing.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Ponatinib (Iclusig&#9660;) is a treatment for adults with chronic myeloid leukaemia or Philadelphia-chromosome-positive acute lymphoblastic leukaemia. The medicine&#8217;s authorised use is restricted to patients who have limited alternative treatment options with tyrosine kinase inhibitors. For full information on the authorised indication, please refer to the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002695/human_med_001656.jsp&#38;mid=WC0b01ac058001d124\" target=\"_blank\">Summary of Product Characteristics</a>.</p>\n\n<p>A review of the latest data has been conducted after new information suggested that vascular occlusive events occur at a higher cumulative incidence than initially observed at the time of licensing. The cumulative incidence of arterial and venous thrombotic events has increased with longer-term follow-up of patients in ongoing phase I and II clinical trials. Furthermore, preliminary data from a recently discontinued phase III comparison of ponatinib with imatinib have shown a higher number of vascular occlusive events in the ponatinib group. These events include: cardiovascular; cerebrovascular; and peripheral vascular adverse events, and venous thrombotic events.</p>\n\n<p>These events occurred in patients with or without cardiovascular risk factors, including those age 50 years or younger. Vascular occlusive adverse events were more frequent with increasing age and in patients with a history of myocardial infarction, stroke, hypertension, diabetes, or hyperlipidaemia.</p>\n\n<p>The European Medicines Agency now plans to review in more detail the balance of risks and benefits of ponatinib.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul type=\"disc\">\n<li>Ponatinib should not be used in patients with a history of myocardial infarction or stroke, unless the potential benefit of treatment outweighs the potential risk</li>\n\n<li>Cardiovascular status of patients should be assessed, and cardiovascular risk factors should be actively managed before starting treatment with ponatinib. Cardiovascular status should continue to be monitored and optimised during treatment</li>\n\n<li>Hypertension should be medically controlled during ponatinib treatment, interruption of which should be considered if hypertension is not controlled</li>\n\n<li>Patients should be monitored for evidence of vascular occlusion or thromboembolism, and treatment should be interrupted immediately if this occurs</li>\n\n<li>Suspected adverse reactions to ponatinib should be reported to us on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Information from the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001986.jsp&#38;mid=WC0b01ac058004d5c1\" target=\"_blank\">European Medicines Agency</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 5, December 2013: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Ponatinib (Iclusig&#9660;) is a treatment for adults with chronic myeloid leukaemia or Philadelphia-chromosome-positive acute lymphoblastic leukaemia. The medicine&#8217;s authorised use is restricted to patients who have limited alternative treatment options with tyrosine kinase inhibitors. For full information on the authorised indication, please refer to the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002695/human_med_001656.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">Summary of Product Characteristics</a>.</p>\n\n<p>A review of the latest data has been conducted after new information suggested that vascular occlusive events occur at a higher cumulative incidence than initially observed at the time of licensing. The cumulative incidence of arterial and venous thrombotic events has increased with longer-term follow-up of patients in ongoing phase I and II clinical trials. Furthermore, preliminary data from a recently discontinued phase III comparison of ponatinib with imatinib have shown a higher number of vascular occlusive events in the ponatinib group. These events include: cardiovascular; cerebrovascular; and peripheral vascular adverse events, and venous thrombotic events.</p>\n\n<p>These events occurred in patients with or without cardiovascular risk factors, including those age 50 years or younger. Vascular occlusive adverse events were more frequent with increasing age and in patients with a history of myocardial infarction, stroke, hypertension, diabetes, or hyperlipidaemia.</p>\n\n<p>The European Medicines Agency now plans to review in more detail the balance of risks and benefits of ponatinib.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul type=\"disc\">\n<li>Ponatinib should not be used in patients with a history of myocardial infarction or stroke, unless the potential benefit of treatment outweighs the potential risk</li>\n\n<li>Cardiovascular status of patients should be assessed, and cardiovascular risk factors should be actively managed before starting treatment with ponatinib. Cardiovascular status should continue to be monitored and optimised during treatment</li>\n\n<li>Hypertension should be medically controlled during ponatinib treatment, interruption of which should be considered if hypertension is not controlled</li>\n\n<li>Patients should be monitored for evidence of vascular occlusion or thromboembolism, and treatment should be interrupted immediately if this occurs</li>\n\n<li>Suspected adverse reactions to ponatinib should be reported to us on a Yellow Card (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Information from the <a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001986.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">European Medicines Agency</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 5, December 2013: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-12-01", 
  "date_last_modified": "2013-12-13", 
  "_assets": [], 
  "_item_id": 44, 
  "summary": "", 
  "body": "Article date: December 2013\n\nPonatinib (Iclusig▼) is a treatment for adults with chronic myeloid leukaemia or Philadelphia-chromosome-positive acute lymphoblastic leukaemia. The medicine’s authorised use is restricted to patients who have limited alternative treatment options with tyrosine kinase inhibitors. For full information on the authorised indication, please refer to the [Summary of Product Characteristics](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002695/human_med_001656.jsp&mid=WC0b01ac058001d124).\n\nA review of the latest data has been conducted after new information suggested that vascular occlusive events occur at a higher cumulative incidence than initially observed at the time of licensing. The cumulative incidence of arterial and venous thrombotic events has increased with longer-term follow-up of patients in ongoing phase I and II clinical trials. Furthermore, preliminary data from a recently discontinued phase III comparison of ponatinib with imatinib have shown a higher number of vascular occlusive events in the ponatinib group. These events include: cardiovascular; cerebrovascular; and peripheral vascular adverse events, and venous thrombotic events.\n\nThese events occurred in patients with or without cardiovascular risk factors, including those age 50 years or younger. Vascular occlusive adverse events were more frequent with increasing age and in patients with a history of myocardial infarction, stroke, hypertension, diabetes, or hyperlipidaemia.\n\nThe European Medicines Agency now plans to review in more detail the balance of risks and benefits of ponatinib.\n\nAdvice for healthcare professionals:  \n  \n  * Ponatinib should not be used in patients with a history of myocardial infarction or stroke, unless the potential benefit of treatment outweighs the potential risk  \n  * Cardiovascular status of patients should be assessed, and cardiovascular risk factors should be actively managed before starting treatment with ponatinib. Cardiovascular status should continue to be monitored and optimised during treatment  \n  * Hypertension should be medically controlled during ponatinib treatment, interruption of which should be considered if hypertension is not controlled  \n  * Patients should be monitored for evidence of vascular occlusion or thromboembolism, and treatment should be interrupted immediately if this occurs  \n  * Suspected adverse reactions to ponatinib should be reported to us on a Yellow Card ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard))  \n  \nFurther information\n\nInformation from the [European Medicines Agency](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/12/news_detail_001986.jsp&mid=WC0b01ac058004d5c1)\n\n \n\nArticle citation: Drug Safety Update volume 7 issue 5, December 2013: S1.\n"
}